查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1929752

细胞治疗平台市场（按细胞类型、治疗模型、适应症和最终用户划分），全球预测（2026-2032）

Cell therapy platform Market by Cell Type, Therapy Model, Indication, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，细胞治疗平台市场价值将达到 68.4 亿美元，到 2026 年将成长至 80.2 亿美元，到 2032 年将达到 214.5 亿美元，复合年增长率为 17.72%。

关键市场统计数据
基准年 2025 68.4亿美元
预计年份：2026年 80.2亿美元
预测年份 2032 214.5亿美元
复合年增长率 (%) 17.72%

本文简要概述了细胞治疗领域不断演变的现状，包括科学创新、商业化生产和监管复杂性等方面的交汇点。

细胞治疗生态係正步入整合与技术成熟的阶段，科学突破与商业性严谨性在此交汇融合。基因编辑、自动化生产和细胞工程技术的进步拓展了治疗潜力，同时也提高了人们对製程稳健性、法规遵循和长期安全监测的期望。在此背景下，该产业正从以学术研究和早期临床研究为主的环境，转型为涵盖药物发现、GMP生产和真实世界证据收集的整合价值链。

自动化生产、治疗模式多样化、监管法规不断演变以及透过伙伴关係扩大规模，正在重新定义细胞治疗领域的优先事项。

细胞治疗领域正经历一系列变革性转变，这些转变共同改变了研发重点和商业性机会。首先，生产製程的模组化和封闭式自动化系统的引入降低了製程变异性，并实现了高通量生产，同时确保了产品品质。载体设计、基因编辑精准性和细胞分选技术的进步进一步增强了疗效，减少了脱靶效应，从而强化了更广泛适应症的临床证据。

评估2025年关税变化和贸易趋势如何影响细胞疗法供应链策略、国内生产能力投资和临床物流。

贸易和关税政策的变化会对高科技生物製造和临床供应链产生显着的下游影响。美国2025年宣布的关税措施的累积影响，为依赖进口试剂、专用设备和耗材的相关人员带来了新的成本压力和策略性贸易考量。对于那些从国际采购病毒载体生产系统、一次性组件和仪器的开发商和契约製造而言，不断上涨的进口成本和日益复杂的海关手续正促使他们重新评估供应商组合，并加快国内供应商的资格认证。

详细的細項分析揭示了细胞类型多样性、治疗模型、适应症和终端用户管道如何共同决定研发和商业化路径。

精细的细分技术揭示了细胞疗法模式、治疗模型、适应症和最终用户中科学机会与商业性可行性的交集。依细胞类型划分，这些疗法包括CAR-T细胞、树突细胞、造血干细胞、间质干细胞、TCR T细胞和肿瘤浸润淋巴细胞。 CAR-T细胞进一步细分为第一代、第二代、第三代和第四代构建体，而间质干细胞则来自脂肪组织、骨髓、牙髓和脐带。每种细胞类型都具有独特的生物学优势和生产要求，这些优势和要求会影响其临床定位。例如，CAR-T技术在血液肿瘤学应用领域持续主导，其中工程化受体发挥强大的肿瘤定向细胞毒性作用；而间质干细胞和造血干细胞在再生医学和免疫调节适应症中发挥着重要作用，这些适应症需要不同的疗效测试和储存期考虑。

政策趋势、製造业投资和监管现代化在关键地区如何影响在地化打入市场策略和规模化扩大策略

在美洲、欧洲、中东和非洲以及亚太地区，区域趋势对企业优先考虑製造地、临床试验地点和打入市场策略起着关键作用。在美洲，强大的创业投资和机构资本生态系统，以及针对特定适应症的加速核准监管途径，持续推动临床创新，并促进公私合营，以提升生产能力。该地区的监管工作重点在于与国际标准接轨，并为变革性治疗方法建立更快速的准入途径。

策略性企业行为和竞争模式揭示了平台创新、策略伙伴关係以及合约研发生产组织（CDMO）的崛起如何塑造产业领导地位。

细胞治疗领域的竞争由众多参与者推动，包括平台技术开发商、临床阶段生物技术公司、大型製药合作伙伴以及专业的合约研发生产力机构。平台开发商正大力投资于新一代载体设计、细胞编辑工具和效力检测，以期透过提升疗效和安全性来脱颖而出；而临床阶段公司则优先考虑那些疗效显着、能够加快与监管机构和支付方沟通的适应症。

为经营团队制定可操作的策略重点，将可製造性、供应弹性、支付方参与和合作伙伴关係纳入其发展计画。

细胞治疗生态系统中的领导者必须采取务实且具前瞻性的策略，将科学创新与商业性可行性结合。首先，企业应在研发週期的早期阶段优先考虑可生产性。透过将製程开发和分析策略整合到药物发现计画中，临床候选药物不仅要评估其生物学原理，还要评估其可扩展性和监管合规性。这种方法可以降低后期技术风险，并支援快速过渡到符合GMP标准的生产。

研究采用透明的调查方法，结合一手访谈、二手文献回顾、比较流程图绘製和情境分析，以支持可靠的研究结果。

本报告的研究结合了定性和定量方法，以确保获得全面且检验的见解。主要研究包括对治疗药物研发公司、生产服务供应商、临床研究人员、监管专家和报销专家的资深管理人员进行结构化访谈，以收集关于技术挑战、策略重点和营运限制的第一手观点。次要研究包括对同行评审文献、监管指导文件、临床试验註册库和上市公司披露资讯进行系统性回顾，以检验趋势并为专家意见提供背景资讯。

整合科学进步、严谨的营运和策略伙伴关係，以确定哪些细胞疗法能够实现临床和商业性的可持续​​性。

总体而言，细胞治疗领域正从以科学发现为特征的阶段向以大规模应用为特征的阶段过渡。细胞工程和製造技术的进步正与商业性和监管要求相融合，这要求在产品开发、供应链设计和证据生成方面采取更严谨的方法。那些能够将早期创新与务实的生产流程和以支付方为中心的临床策略相结合的机构，将能够更好地应对监管核准和市场进入的复杂性。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依细胞类型分類的细胞治疗平台市场

  • CAR T 细胞
    • 第一代
    • 第四代
    • 第二代
    • 第三代
  • 树突状细胞
  • 造血干细胞
  • 间质干细胞
    • 脂肪组织
    • 骨髓
    • 纸浆
    • 脐带
  • 自然杀手细胞
  • Tcr T细胞
  • 肿瘤浸润淋巴细胞

9. 按治疗模式分類的细胞治疗平台市场

  • 异体细胞疗法
  • 自体细胞疗法

第十章 细胞治疗平台市场（依适应症划分）

  • 循环系统
  • 免疫学
  • 神经系统
  • 肿瘤学
  • 整形外科

第十一章 按最终用户分類的细胞治疗平台市场

  • CRO（受託研究机构）
  • 医院
  • 研究所
  • 专科诊所

第十二章 细胞治疗平台市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 细胞治疗平台市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国细胞治疗平台市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国细胞治疗平台市场

第十六章：中国细胞治疗平台市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Adaptimmune Therapeutics plc
  • Allogene Therapeutics Inc.
  • Atara Biotherapeutics Inc.
  • Autolus Therapeutics plc
  • Beam Therapeutics Inc.
  • Bluebird Bio Inc.
  • Bristol-Myers Squibb Company
  • Century Therapeutics Inc.
  • CRISPR Therapeutics AG
  • Editas Medicine Inc.
  • Fate Therapeutics Inc.
  • Gilead Sciences Inc.
  • Intellia Therapeutics Inc.
  • Iovance Biotherapeutics Inc.
  • Johnson & Johnson
  • Legend Biotech Corporation
  • Nkarta Inc.
  • Novartis AG
  • Sana Biotechnology Inc.
Product Code: MRR-0A3806951A1D

The Cell therapy platform Market was valued at USD 6.84 billion in 2025 and is projected to grow to USD 8.02 billion in 2026, with a CAGR of 17.72%, reaching USD 21.45 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.84 billion
Estimated Year [2026] USD 8.02 billion
Forecast Year [2032] USD 21.45 billion
CAGR (%) 17.72%

A concise orientation to the evolving cell therapy landscape where scientific innovation intersects with commercial-scale production and regulatory complexity

The cell therapy ecosystem is entering a phase of consolidation and technological maturation where scientific breakthroughs meet commercial rigor. Advances in gene editing, manufacturing automation, and cell engineering are expanding therapeutic possibility while concurrently raising expectations around process robustness, regulatory compliance, and long-term safety monitoring. Against this backdrop, the industry is shifting from a predominantly academic and early-stage clinical landscape toward integrated value chains that span discovery, GMP manufacturing, and real-world evidence collection.

As investment continues to flow into platform technologies and clinical-stage programs, stakeholders must balance aggressive innovation with scalable production and reimbursement strategies. The interplay between novel modalities such as chimeric antigen receptor therapies, engineered natural killer approaches, and stem-cell-based regenerative applications is creating both competition and complementarity across therapeutic and manufacturing domains. Consequently, strategic planning now requires a cross-functional perspective that connects scientific development with supply chain resilience, regulatory pathways, and patient access considerations.

Looking ahead, the sector's ability to demonstrate consistent clinical benefit, control manufacturing costs, and navigate regulatory complexity will determine which technologies transition from proof-of-concept to standard-of-care. Leaders that align R&D priorities with manufacturability, regulatory strategy, and payer engagement will be best positioned to translate scientific promise into sustainable clinical and commercial impact.

How manufacturing automation, diversified therapy models, regulatory evolution, and partnership-driven scale are redefining priorities across the cell therapy sector

The landscape for cell therapies is being reshaped by a set of transformative shifts that collectively alter development priorities and commercial opportunities. First, modularization of manufacturing processes and the adoption of closed, automated systems are reducing process variability and enabling higher throughput while preserving product quality. This shift is complemented by advances in vector design, gene editing precision, and cell selection technologies that improve potency and reduce off-target effects, thus strengthening the clinical rationale for broader indications.

Second, therapy models are diversifying. Allogeneic approaches are gaining traction as developers pursue off-the-shelf solutions that can reduce time-to-treatment and standardize product performance, while autologous strategies remain important for highly personalized interventions where immunologic compatibility is critical. Third, regulatory frameworks are evolving to address long-term follow-up and real-world safety, prompting sponsors to invest earlier in data systems and patient registries that can support post-approval evidence generation.

Finally, strategic partnerships and outsourcing are becoming more central. Biopharma companies, contract development and manufacturing organizations, and specialty clinics are co-creating pathways to scale clinical programs and accelerate commercial readiness. Taken together, these shifts are steering the industry toward more interoperable, cost-efficient, and clinically rigorous approaches that increase the feasibility of delivering cell therapies at scale.

Assessing how 2025 tariff changes and trade dynamics are reshaping supply chain strategies, domestic capacity investments, and clinical logistics for cell therapies

Policy changes in trade and tariff regimes can create material downstream effects across high-technology biomanufacturing and clinical supply chains. The cumulative impact of United States tariffs announced in 2025 has introduced new cost pressures and strategic trade considerations for stakeholders that depend on imported reagents, specialized equipment, and consumables. For developers and contract manufacturers that source viral vector production systems, single-use assemblies, and instrumentation internationally, higher import costs and customs complexity have increased the incentive to reassess supplier portfolios and to accelerate qualification of domestic vendors.

In practice, these dynamics have prompted companies to pursue several mitigation strategies. Some organizations are revisiting their sourcing strategies to diversify suppliers geographically and to pre-qualify alternative materials that meet regulatory requirements. Others are accelerating investments in local manufacturing capacity and regionalized supply chains to reduce exposure to tariff volatility and transit delays. At the same time, clinical programs that rely on cross-border logistics for patient cells, cryopreservation, and central lab testing have had to strengthen cold-chain contingency plans and documentation controls to avoid trial interruptions.

Regulatory authorities and industry groups have responded by emphasizing transparent customs documentation, harmonized quality standards, and expedited approvals for validated local suppliers. Going forward, the combined effect of tariffs and shifting geopolitical trade dynamics is likely to favor vertically integrated players and regional manufacturing hubs that can absorb supply shocks, maintain product continuity, and offer predictable timelines to clinical sites and payers.

In-depth segmentation analysis illuminating how cell type diversity, therapy models, indications, and end-user channels jointly determine development and commercialization pathways

A nuanced segmentation approach reveals where scientific opportunity and commercial feasibility converge across cell therapy modalities, therapy models, indications, and end users. By cell type, the landscape includes CAR T cells, dendritic cells, hematopoietic stem cells, mesenchymal stem cells, natural killer cells, TCR T cells, and tumor infiltrating lymphocytes, with CAR T further differentiated into first, second, third, and fourth generation constructs and mesenchymal stem cells sourced from adipose tissue, bone marrow, dental pulp, and umbilical cord. Each cell type exhibits distinct biological advantages and manufacturing requirements that influence clinical positioning: for example, CAR T technologies continue to lead in hematologic oncology applications where engineered receptors deliver potent tumor-directed cytotoxicity, whereas mesenchymal and hematopoietic stem cells play prominent roles in regenerative and immunomodulatory indications that require different potency assays and shelf-life considerations.

Therapy model segmentation between allogeneic and autologous approaches underscores a strategic trade-off between scalability and personalization. Allogeneic therapies present opportunities for standardized manufacturing and rapid delivery but require rigorous immunogenicity control, while autologous therapies demand individualized logistics and robust chain-of-identity systems. Indication-based segmentation across cardiovascular, immunology, neurological, oncology, and orthopedic applications highlights distinct clinical endpoints, trial designs, and regulatory pathways; oncology programs often follow accelerated clinical timelines based on objective response rates, while regenerative indications emphasize functional and long-term durability outcomes.

End-user segmentation-spanning contract research organizations, hospitals, research institutes, and specialty clinics-reflects the operational diversity of the field. CROs and CDMOs are increasingly central to translating early-stage science into GMP-ready processes, hospitals provide critical infrastructure for complex administration and inpatient care, research institutes continue to drive discovery and early translation, and specialty clinics are emerging as hubs for outpatient delivery of select cell therapies. Understanding these segment intersections enables more precise alignment of clinical strategy, manufacturing investments, and commercialization pathways.

How regional policy, manufacturing investment, and regulatory modernization across major geographies are informing tailored market entry and scale strategies

Regional dynamics are shaping how companies prioritize manufacturing footprints, clinical trial sites, and market-entry strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, robust venture and institutional capital ecosystems, coupled with established regulatory pathways for expedited approvals in certain indications, continue to sustain clinical innovation and foster strong private-public partnerships to build manufacturing capacity. Regulatory engagement in this region emphasizes harmonization with international standards and expedited access pathways for transformative therapies.

Europe, Middle East & Africa present a complex mosaic of opportunities and challenges where centralized regulatory frameworks coexist with diverse national reimbursement regimes. Several European countries are advancing adaptive payment models and coverage-with-evidence arrangements that can support earlier patient access while simultaneously encouraging rigorous long-term data collection. Regional consortiums and collaborative manufacturing networks are also forming to support cross-border supply reliability and to reduce duplication of expensive infrastructure.

Asia-Pacific is characterized by a rapid expansion of biomanufacturing capacity, proactive regulatory modernization, and a large patient population that can accelerate clinical enrollment. Governments in key countries are incentivizing domestic production and public-private collaboration, which in turn drives localized supply chains and growing clinical trial activity. Taken together, these regional trends are encouraging hybrid strategies that combine global R&D with region-specific manufacturing and market-access plans to optimize speed to patient and commercial sustainability.

Strategic company behaviors and competitive patterns revealing how platform innovation, strategic partnerships, and CDMO expansion are shaping sector leadership

Competitive dynamics in the cell therapy sector are driven by a spectrum of players including platform technology developers, clinical-stage biotechs, large pharmaceutical partners, and specialized contract development and manufacturing organizations. Platform developers are investing heavily in next-generation vector design, cell editing tools, and potency assays to differentiate through improved efficacy and safety profiles, while clinical-stage companies are prioritizing indications where compelling efficacy signals can enable regulatory acceleration and payer conversations.

Large pharmaceutical companies are increasingly entering the space through strategic alliances, licensing, and acquisitions, leveraging their commercial infrastructure to support late-stage development and market access. Meanwhile, CDMOs and CDMOs with cell therapy-specific capabilities are expanding capacity, investing in closed systems and automation, and offering end-to-end services that de-risk scale-up for emerging sponsors. Academic spinouts and nimble startups continue to advance scientific novelty in areas such as NK cell engineering and TCR therapies, often partnering with specialized manufacturers to bridge the gap to clinical testing.

Across this competitive landscape, success hinges on integrated capabilities: robust CMC development, GMP-compliant manufacturing networks, well-defined regulatory strategies, and clear evidence-generation plans that speak to both regulators and payers. Companies that can align scientific differentiation with operational excellence and payer-engaged clinical endpoints will be positioned to capture long-term value as the field matures.

Actionable strategic priorities for executives to integrate manufacturability, supply resilience, payer engagement, and collaborative partnerships into development plans

Leaders in the cell therapy ecosystem must adopt pragmatic, forward-looking strategies that bridge scientific innovation and commercial viability. First, companies should prioritize manufacturability early in the R&D cycle by integrating process development and analytical strategy into discovery programs so that clinical candidates are assessed not only on biological rationale but also on scalability and regulatory tractability. This approach reduces late-stage technical risk and supports faster transition to GMP manufacturing.

Second, supply chain resilience should be a core strategic objective. Diversifying suppliers, qualifying regional partners, and investing in modular, automated manufacturing platforms can mitigate tariff-driven and geopolitical disruptions. Third, organizations should proactively engage payers and health technology assessment bodies to design clinical programs that generate the types of endpoints and real-world evidence required for sustainable reimbursement, including adaptive payment models and outcomes-based agreements where appropriate.

Finally, executives should cultivate collaborative ecosystems that align biotech innovators, manufacturing specialists, clinical networks, and regulatory advisors. Strategic alliances and selective M&A can accelerate access to critical capabilities while preserving focus on scientific differentiation. By executing on these actions, leaders can reduce time-to-clinic, de-risk commercialization, and enhance patient access to transformative therapies.

Transparent research methodology combining primary interviews, secondary literature review, comparative process mapping, and scenario analysis to support robust insights

The research underpinning this report combined qualitative and quantitative approaches to ensure comprehensive and verifiable findings. Primary research included structured interviews with senior executives across therapeutic developers, manufacturing service providers, clinical investigators, regulatory experts, and reimbursement specialists to capture first-hand perspectives on technological challenges, strategic priorities, and operational constraints. Secondary research involved a systematic review of peer-reviewed literature, regulatory guidance documents, clinical trial registries, and public company disclosures to validate trends and to contextualize expert input.

Analytical methods included comparative process mapping to identify common manufacturing bottlenecks, scenario analysis to explore the effects of trade policy and supply-chain disruption, and cross-segmentation synthesis to reveal where modality, therapy model, and indication intersect to shape strategic choices. Care was taken to triangulate findings across multiple sources and to document assumptions related to clinical development pathways, manufacturing feasibility, and regulatory timing. Limitations and confidence levels for specific thematic conclusions are explicitly noted, and readers can request supplemental methodological appendices that detail interview lists, data triangulation steps, and analytic templates used to derive the insights.

Synthesis of how scientific advances, operational rigor, and strategic partnerships will determine which cell therapies achieve clinical and commercial longevity

In aggregate, the cell therapy arena is transitioning from a period defined by scientific discovery to one defined by delivery at scale. Technical progress in cell engineering and manufacturing is converging with commercial and regulatory imperatives, which necessitates a more disciplined approach to product development, supply-chain design, and evidence generation. Organizations that align early-stage innovation with pragmatic manufacturing and payer-focused clinical strategies will better navigate the complexities of regulatory approval and market access.

Geopolitical and trade developments underscore the value of regionalized manufacturing and diversified supplier networks, while advances in automation and analytics offer pathways to control variability and reduce per-dose complexity. Partnerships across the ecosystem-between innovators, contract manufacturers, clinical sites, and payers-remain essential to accelerate patient access and to distribute risk. Ultimately, the capacity to translate technical differentiation into reproducible manufacturing processes, credible clinical evidence, and sustainable reimbursement models will determine which technologies achieve widespread clinical adoption and durable commercial success.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cell therapy platform Market, by Cell Type

  • 8.1. CAR T Cells
    • 8.1.1. First Generation
    • 8.1.2. Fourth Generation
    • 8.1.3. Second Generation
    • 8.1.4. Third Generation
  • 8.2. Dendritic Cells
  • 8.3. Hematopoietic Stem Cells
  • 8.4. Mesenchymal Stem Cells
    • 8.4.1. Adipose Tissue
    • 8.4.2. Bone Marrow
    • 8.4.3. Dental Pulp
    • 8.4.4. Umbilical Cord
  • 8.5. Natural Killer Cells
  • 8.6. Tcr T Cells
  • 8.7. Tumor Infiltrating Lymphocytes

9. Cell therapy platform Market, by Therapy Model

  • 9.1. Allogeneic Cell Therapy
  • 9.2. Autologous Cell Therapy

10. Cell therapy platform Market, by Indication

  • 10.1. Cardiovascular
  • 10.2. Immunology
  • 10.3. Neurological
  • 10.4. Oncology
  • 10.5. Orthopedic

11. Cell therapy platform Market, by End User

  • 11.1. Contract Research Organizations
  • 11.2. Hospitals
  • 11.3. Research Institutes
  • 11.4. Specialty Clinics

12. Cell therapy platform Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Cell therapy platform Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Cell therapy platform Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Cell therapy platform Market

16. China Cell therapy platform Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Adaptimmune Therapeutics plc
  • 17.6. Allogene Therapeutics Inc.
  • 17.7. Atara Biotherapeutics Inc.
  • 17.8. Autolus Therapeutics plc
  • 17.9. Beam Therapeutics Inc.
  • 17.10. Bluebird Bio Inc.
  • 17.11. Bristol-Myers Squibb Company
  • 17.12. Century Therapeutics Inc.
  • 17.13. CRISPR Therapeutics AG
  • 17.14. Editas Medicine Inc.
  • 17.15. Fate Therapeutics Inc.
  • 17.16. Gilead Sciences Inc.
  • 17.17. Intellia Therapeutics Inc.
  • 17.18. Iovance Biotherapeutics Inc.
  • 17.19. Johnson & Johnson
  • 17.20. Legend Biotech Corporation
  • 17.21. Nkarta Inc.
  • 17.22. Novartis AG
  • 17.23. Sana Biotechnology Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CELL THERAPY PLATFORM MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CELL THERAPY PLATFORM MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY CELL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY THERAPY MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CELL THERAPY PLATFORM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CELL THERAPY PLATFORM MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY CAR T CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY CAR T CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY CAR T CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY CAR T CELLS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY FOURTH GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY FOURTH GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY FOURTH GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY DENDRITIC CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY DENDRITIC CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY DENDRITIC CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY ADIPOSE TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY ADIPOSE TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY ADIPOSE TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY BONE MARROW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY BONE MARROW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY BONE MARROW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY DENTAL PULP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY DENTAL PULP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY DENTAL PULP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY UMBILICAL CORD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY UMBILICAL CORD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY UMBILICAL CORD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY NATURAL KILLER CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY NATURAL KILLER CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY NATURAL KILLER CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY TCR T CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY TCR T CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY TCR T CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY TUMOR INFILTRATING LYMPHOCYTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY TUMOR INFILTRATING LYMPHOCYTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY TUMOR INFILTRATING LYMPHOCYTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY THERAPY MODEL, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY ALLOGENEIC CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY ALLOGENEIC CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY ALLOGENEIC CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY IMMUNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY IMMUNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY NEUROLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY NEUROLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY NEUROLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY ORTHOPEDIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY ORTHOPEDIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY ORTHOPEDIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS CELL THERAPY PLATFORM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS CELL THERAPY PLATFORM MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS CELL THERAPY PLATFORM MARKET SIZE, BY CAR T CELLS, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS CELL THERAPY PLATFORM MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS CELL THERAPY PLATFORM MARKET SIZE, BY THERAPY MODEL, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS CELL THERAPY PLATFORM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS CELL THERAPY PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA CELL THERAPY PLATFORM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA CELL THERAPY PLATFORM MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA CELL THERAPY PLATFORM MARKET SIZE, BY CAR T CELLS, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA CELL THERAPY PLATFORM MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA CELL THERAPY PLATFORM MARKET SIZE, BY THERAPY MODEL, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA CELL THERAPY PLATFORM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA CELL THERAPY PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA CELL THERAPY PLATFORM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA CELL THERAPY PLATFORM MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA CELL THERAPY PLATFORM MARKET SIZE, BY CAR T CELLS, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA CELL THERAPY PLATFORM MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA CELL THERAPY PLATFORM MARKET SIZE, BY THERAPY MODEL, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA CELL THERAPY PLATFORM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA CELL THERAPY PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY PLATFORM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY PLATFORM MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY PLATFORM MARKET SIZE, BY CAR T CELLS, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY PLATFORM MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY PLATFORM MARKET SIZE, BY THERAPY MODEL, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY PLATFORM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE CELL THERAPY PLATFORM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE CELL THERAPY PLATFORM MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE CELL THERAPY PLATFORM MARKET SIZE, BY CAR T CELLS, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE CELL THERAPY PLATFORM MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE CELL THERAPY PLATFORM MARKET SIZE, BY THERAPY MODEL, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE CELL THERAPY PLATFORM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE CELL THERAPY PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST CELL THERAPY PLATFORM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST CELL THERAPY PLATFORM MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST CELL THERAPY PLATFORM MARKET SIZE, BY CAR T CELLS, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST CELL THERAPY PLATFORM MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST CELL THERAPY PLATFORM MARKET SIZE, BY THERAPY MODEL, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST CELL THERAPY PLATFORM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST CELL THERAPY PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA CELL THERAPY PLATFORM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA CELL THERAPY PLATFORM MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA CELL THERAPY PLATFORM MARKET SIZE, BY CAR T CELLS, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA CELL THERAPY PLATFORM MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA CELL THERAPY PLATFORM MARKET SIZE, BY THERAPY MODEL, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA CELL THERAPY PLATFORM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA CELL THERAPY PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC CELL THERAPY PLATFORM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC CELL THERAPY PLATFORM MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC CELL THERAPY PLATFORM MARKET SIZE, BY CAR T CELLS, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC CELL THERAPY PLATFORM MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC CELL THERAPY PLATFORM MARKET SIZE, BY THERAPY MODEL, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC CELL THERAPY PLATFORM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC CELL THERAPY PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN CELL THERAPY PLATFORM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN CELL THERAPY PLATFORM MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN CELL THERAPY PLATFORM MARKET SIZE, BY CAR T CELLS, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN CELL THERAPY PLATFORM MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN CELL THERAPY PLATFORM MARKET SIZE, BY THERAPY MODEL, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN CELL THERAPY PLATFORM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN CELL THERAPY PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. GCC CELL THERAPY PLATFORM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GCC CELL THERAPY PLATFORM MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. GCC CELL THERAPY PLATFORM MARKET SIZE, BY CAR T CELLS, 2018-2032 (USD MILLION)
  • TABLE 154. GCC CELL THERAPY PLATFORM MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 155. GCC CELL THERAPY PLATFORM MARKET SIZE, BY THERAPY MODEL, 2018-2032 (USD MILLION)
  • TABLE 156. GCC CELL THERAPY PLATFORM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 157. GCC CELL THERAPY PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION CELL THERAPY PLATFORM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION CELL THERAPY PLATFORM MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION CELL THERAPY PLATFORM MARKET SIZE, BY CAR T CELLS, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION CELL THERAPY PLATFORM MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION CELL THERAPY PLATFORM MARKET SIZE, BY THERAPY MODEL, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION CELL THERAPY PLATFORM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION CELL THERAPY PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS CELL THERAPY PLATFORM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS CELL THERAPY PLATFORM MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS CELL THERAPY PLATFORM MARKET SIZE, BY CAR T CELLS, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS CELL THERAPY PLATFORM MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS CELL THERAPY PLATFORM MARKET SIZE, BY THERAPY MODEL, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS CELL THERAPY PLATFORM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS CELL THERAPY PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. G7 CELL THERAPY PLATFORM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. G7 CELL THERAPY PLATFORM MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. G7 CELL THERAPY PLATFORM MARKET SIZE, BY CAR T CELLS, 2018-2032 (USD MILLION)
  • TABLE 175. G7 CELL THERAPY PLATFORM MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 176. G7 CELL THERAPY PLATFORM MARKET SIZE, BY THERAPY MODEL, 2018-2032 (USD MILLION)
  • TABLE 177. G7 CELL THERAPY PLATFORM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 178. G7 CELL THERAPY PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. NATO CELL THERAPY PLATFORM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. NATO CELL THERAPY PLATFORM MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. NATO CELL THERAPY PLATFORM MARKET SIZE, BY CAR T CELLS, 2018-2032 (USD MILLION)
  • TABLE 182. NATO CELL THERAPY PLATFORM MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 183. NATO CELL THERAPY PLATFORM MARKET SIZE, BY THERAPY MODEL, 2018-2032 (USD MILLION)
  • TABLE 184. NATO CELL THERAPY PLATFORM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 185. NATO CELL THERAPY PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL CELL THERAPY PLATFORM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES CELL THERAPY PLATFORM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES CELL THERAPY PLATFORM MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES CELL THERAPY PLATFORM MARKET SIZE, BY CAR T CELLS, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES CELL THERAPY PLATFORM MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES CELL THERAPY PLATFORM MARKET SIZE, BY THERAPY MODEL, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES CELL THERAPY PLATFORM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES CELL THERAPY PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA CELL THERAPY PLATFORM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA CELL THERAPY PLATFORM MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA CELL THERAPY PLATFORM MARKET SIZE, BY CAR T CELLS, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA CELL THERAPY PLATFORM MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA CELL THERAPY PLATFORM MARKET SIZE, BY THERAPY MODEL, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA CELL THERAPY PLATFORM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA CELL THERAPY PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)